Editorial : Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 59(2024), 6 vom: 15. Feb., Seite 794 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vasudevan, Abhinav [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2-mercaptopurine |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.17895 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368911195 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368911195 | ||
| 003 | DE-627 | ||
| 005 | 20240229155858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.17895 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM368911195 | ||
| 035 | |a (NLM)38401137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vasudevan, Abhinav |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Editorial |b Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 7 | |a 2-mercaptopurine |2 NLM | |
| 650 | 7 | |a 81XK02929C |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Sulfhydryl Compounds |2 NLM | |
| 700 | 1 | |a Con, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a van Langenberg, Daniel R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 59(2024), 6 vom: 15. Feb., Seite 794 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:6 |g day:15 |g month:02 |g pages:794 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.17895 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |e 6 |b 15 |c 02 |h 794 | ||